UBT251
Intervention2 papers8 findings
C · W · M · H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.
Company ties: findings with an author at a company, or from a paper that declares the maker’s interest.
Funder: Transnationale Universiteit Limburg8 of 8 findings with company ties
- Human trial2
Outcomes
7Body weight
downin humans2
2 studies
Body weight
downin humans2
UBT251 decreases body weight in humans (−19.7% to −13.6% versus −2.0% with placebo; placebo-adjusted differences −17.7% to −11.5%).
Human trialAdults with overweight or obesity without type 2 diabetes; compared with placebo2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
UBT251 decreases body weight in humans (-8.96 to -13.48 kg vs +1.57 kg).
Human trialin participants with overweight or obesity without diabetes12 weeks
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study · Diabetes, obesity & metabolism · 8 Sep 2026
Glycemic parameters
upin humans1
1 study
Glycemic parameters
upin humans1
UBT251 improves glycemic parameters in humans.
Human trialAdults with overweight or obesity without type 2 diabetes2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
Lipid profile
upin humans1
1 study
Lipid profile
upin humans1
UBT251 improves lipid profile in humans.
Human trialAdults with overweight or obesity without type 2 diabetes2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
Blood pressure
upin humans1
1 study
Blood pressure
upin humans1
UBT251 improves blood pressure in humans.
Human trialAdults with overweight or obesity without type 2 diabetes2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
Waist circumference
downin humans1
1 study
Waist circumference
downin humans1
UBT251 decreases waist circumference in humans.
Human trialAdults with overweight or obesity without type 2 diabetes2 mg, 4 mg, or 6 mg once weekly24 weeks59.0% womensn = 205
A triple-target drug cut body weight by up to 19.7% in a trial · Cell metabolism · 7 Oct 2026
HbA1c
downin humans1
1 study
HbA1c
downin humans1
UBT251 decreases HbA1c in humans.
Human trialin participants with overweight or obesity without diabetes12 weeks
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study · Diabetes, obesity & metabolism · 8 Sep 2026
Fasting plasma glucose
downin humans1
1 study
Fasting plasma glucose
downin humans1
UBT251 decreases fasting plasma glucose in humans.
Human trialin participants with overweight or obesity without diabetes12 weeks
Safety, Pharmacokinetics and Pharmacodynamics of the GLP-1/GIP/GCG Receptor Agonist UBT251 Injection: A Randomized, Placebo-Controlled Phase 1a/1b Study · Diabetes, obesity & metabolism · 8 Sep 2026
Latest
2A triple-target drug cut body weight by up to 19.7% in a trial
Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.Average body weight fell between 13.6% and 19.7% across drug doses compared with 2.0% on placebo over 24 weeks.